search
Back to results

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Primary Purpose

Giant Cell Arteritis

Status
Terminated
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Sarilumab SAR153191
Sarilumab matching placebo
Prednisone
Prednisone matching placebo
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Giant Cell Arteritis

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria :

  • Diagnosis of GCA according to European League Against Rheumatism/American College of Rheumatology classification criteria.
  • New onset active disease or refractory active disease.
  • At least one of the symptoms of GCA within 6 weeks of baseline.
  • Either erythrocyte sedimentation rate greater than or equal to (>=) 30 millimeter per hour or C-reactive protein >=10 mg per liter within 6 weeks of baseline.
  • Received or were able to receive prednisone 20-60 mg/day for the treatment of active GCA.

Exclusion criteria:

  • Organ transplantation recipient (except corneas, unless it is within 3 months prior to baseline visit).
  • Major ischemic event, unrelated to GCA, within 12 weeks of screening.
  • Any prior use of the following therapies, for the treatment of GCA:
  • Janus kinase inhibitor (e.g., tofacitinib) within 4 weeks of baseline.
  • Cell-depletion agents (e.g., anti CD20) without evidence of recovery of B cells to baseline level.
  • Abatacept within 8 weeks of baseline.
  • Anakinra within 1 week of baseline.
  • Tumor necrosis factor inhibitors within 2-8 weeks (etanercept within 2 weeks; infliximab, certolizumab, golimumab, or adalimumab within 8 weeks), or less than at least 5 half-lives had elapsed prior to baseline, whichever was longer.
  • Therapeutic failure, including inadequate response or intolerance, or contraindication, to biological Interleukin 6 (IL-6) IL-6/(R) antagonist (prior experience with IL-6/(R) antagonist that was terminated for reasons unrelated to therapeutic failure at least 3 months before baseline was not exclusionary).
  • Use of any alkylating agents including cyclophosphamide within 6 months of baseline.
  • Use of immunosuppressant, such as hydroxychloroquine, cyclosporine, azathioprine, mycophenolate mofetil or leflunomide within 4 weeks of baseline. (Use of methotrexate (MTX) not exceeding 25 mg per week and had been stable for at least 3 months prior to baseline was not exclusionary).
  • Concurrent use of systemic CS for conditions other than GCA.
  • Use of intervascular CS at a dose equivalent to 100 mg of methylprednisolone or higher within 8 weeks of baseline for GCA therapy.
  • Pregnant or breastfeeding woman.
  • Participants with active or untreated latent tuberculosis.
  • Participants with history of invasive opportunistic infections.
  • Participants with fever associated with infection or chronic, persistent or recurring infections requiring active treatment.
  • Participants with uncontrolled diabetes mellitus.
  • Participants with non-healed or healing skin ulcers.
  • Participants who received any live, attenuated vaccine within 3 months of baseline.
  • Participants who are positive for hepatitis B, hepatitis C and/or HIV.
  • Participants with a history of active or recurrent herpes zoster.
  • Participants with a history of or prior articular or prosthetic joint infection.
  • Prior or current history of malignancy.
  • Participants who have had surgery within 4 weeks of screening or planned surgery during study.
  • Participants with a history of inflammatory bowel disease or severe diverticulitis or previous gastrointestinal perforation..

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Sites / Locations

  • Investigational Site Number 8400002
  • Investigational Site Number 8400017
  • Investigational Site Number 8400014
  • Investigational Site Number 8400018
  • Investigational Site Number 8400019
  • Investigational Site Number 8400011
  • Investigational Site Number 0320001
  • Investigational Site Number 0320002
  • Investigational Site Number 0360003
  • Investigational Site Number 0360006
  • Investigational Site Number 0360001
  • Investigational Site Number 0560001
  • Investigational Site Number 1240007
  • Investigational Site Number 1240010
  • Investigational Site Number 1240001
  • Investigational Site Number 1240005
  • Investigational Site Number 1240003
  • Investigational Site Number 1910001
  • Investigational Site Number 2080002
  • Investigational Site Number 2080003
  • Investigational Site Number 2330001
  • Investigational Site Number 2500005
  • Investigational Site Number 2500002
  • Investigational Site Number 2500003
  • Investigational Site Number 2500007
  • Investigational Site Number 2500001
  • Investigational Site Number 2500006
  • Investigational Site Number 2760001
  • Investigational Site Number 2760002
  • Investigational Site Number 2760003
  • Investigational Site Number 2760004
  • Investigational Site Number 2760007
  • Investigational Site Number 3480001
  • Investigational Site Number 3760006
  • Investigational Site Number 3760004
  • Investigational Site Number 3800001
  • Investigational Site Number 3800005
  • Investigational Site Number 5280007
  • Investigational Site Number 5280005
  • Investigational Site Number 5280009
  • Investigational Site Number 5280001
  • Investigational Site Number 6200001
  • Investigational Site Number 6200005
  • Investigational Site Number 6200004
  • Investigational Site Number 6430005
  • Investigational Site Number 6430002
  • Investigational Site Number 6430003
  • Investigational Site Number 7050001
  • Investigational Site Number 7240010
  • Investigational Site Number 7240011
  • Investigational Site Number 7240014
  • Investigational Site Number 7240016
  • Investigational Site Number 7240015
  • Investigational Site Number 7520001
  • Investigational Site Number 7520003
  • Investigational Site Number 7560002
  • Investigational Site Number 8260006
  • Investigational Site Number 8260004
  • Investigational Site Number 8260003
  • Investigational Site Number 8260005
  • Investigational Site Number 8260011

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Placebo Comparator

Placebo Comparator

Arm Label

Placebo+52 Week Taper

Placebo+26 Week Taper

Sarilumab 150mg q2w+26 Week Taper

Sarilumab 200mg q2w+26 Week Taper

Arm Description

Participants received sarilumab-matching placebo as subcutaneous (SC) injection every 2 weeks (q2w) up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone/prednisone-matching placebo tapering oral daily doses for 52 weeks.

Participants received sarilumab-matching placebo as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.

Participants received sarilumab 150 milligrams (mg) as SC injection q2w up to 52 weeks along with prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.

Participants received sarilumab 200 mg as SC injection q2w up to 52 weeks along with prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.

Outcomes

Primary Outcome Measures

Percentage of Participants Who Achieved Sustained Disease Remission at Week 52
Disease remission was defined as resolution of signs and symptoms of giant cell arteries (GCA), and normalization of C-reactive protein (CRP) (<10 mg/L). Sustained remission was defined as meeting all of the following parameters: achievement of disease remission not later than Week 12, absence of disease flare (defined as recurrence of signs and symptoms attributable to active GCA plus an increase in corticosteroid [CS] dose due to GCA or elevation of erythrocyte sedimentation rate [ESR] attributable to active GCA plus an increase in CS dose due to GCA) from Week 12 through Week 52, normalization of CRP (to <10 mg/L, with absence of successive elevations to >=10 mg/L) from Week 12 through Week 52, and successful adherence to prednisone taper from Week 12 through Week 52.
Percentage of Participants Who Achieved Sustained Disease Remission at Week 24
Disease remission was defined as resolution of signs and symptoms of GCA, and normalization of CRP <10 mg/L. Sustained remission was defined as meeting all of the following parameters: achievement of disease remission not later than Week 12, absence of disease flare (defined as recurrence of signs and symptoms attributable to active GCA plus an increase in CS dose due to GCA, or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA) from Week 12 through Week 24, normalization of CRP (to <10 mg/L, with an absence of successive elevations to >=10 mg/L) from Week 12 through Week 24, and successful adherence to the prednisone taper from Week 12 through Week 24.

Secondary Outcome Measures

Number of Participants With Achievement of Disease Remission up to Week 12: Week 52 Analysis Set
Disease remission was defined as resolution of signs and symptoms of GCA, and normalization of CRP (< 10 mg/L). The status of normalization of CRP (<10 mg/L) was determined based on the last two non-missing post-baseline CRP values measured up to Week 12. If at least one of the value was <10 mg/L, then it was considered as normalization of CRP. Participants who took rescue corticosteroid (CS) due to active GCA prior to Week 12 or who permanently withdrew from the study treatment prior to Week 12 were considered as not achieved disease remission by Week 12.
Number of Participants With Achievement of Disease Remission up to Week 12: Intent-to-treat (ITT) Population
Disease remission was defined as resolution of signs and symptoms of GCA, and normalization of CRP (< 10 mg/L). The status of normalization of CRP (<10 mg/L) was determined based on the last two non-missing post-baseline CRP values measured up to Week 12. If at least one of the value was <10 mg/L, then it was considered as normalization of CRP. Participants who took rescue CS due to active GCA prior to Week 12 or who permanently withdrew from the study treatment prior to Week 12 were considered as not achieved disease remission by Week 12.
Number of Participants With Absence of Disease Flare From Week 12 Through Week 52: Week 52 Analysis Set
Disease flare was defined as either recurrence of signs and symptoms attributable to active GCA plus an increase in CS dose due to GCA, or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA. Number of participants with absence of disease flare from Week 12 through Week 52 were reported.
Number of Participants With Absence of Disease Flare From Week 12 Through Week 24: ITT Population
Disease flare was defined as either recurrence of signs and symptoms attributable to active GCA plus an increase in CS dose due to GCA, or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA. Number of participants with absence of disease flare from Week 12 through Week 24 were reported.
Number of Participants With Normalization of C-Reactive Protein From Week 12 Through Week 52: Week 52 Analysis Set
Normalization of CRP was defined as CRP levels <10 mg/L. If there were two or more consecutive visits with CRP >=10 mg/L, then it was categorized as no normalization of CRP.
Number of Participants With Normalization of C-Reactive Protein (CRP) From Week 12 Through Week 24: ITT Population
Normalization of CRP was defined as CRP levels <10 mg/L. If there were two or more consecutive visits with CRP >=10 mg/L, then it was categorized as no normalization of CRP.
Number of Participants With Successful Adherence to the Prednisone Taper From Week 12 Through Week 52: Week 52 Analysis Set
Successful adherence to the prednisone taper from Week 12 through Week 52 was defined as participants who did not take rescue therapy from Week 12 through Week 52 and might include the use of any excess prednisone (beyond the per protocol CS tapering regimen) with a cumulative dose of <=100 mg (or equivalent), such as those employed to manage adverse event (AE) not related to GCA.
Number of Participants With Successful Adherence to the Prednisone Taper From Week 12 Through Week 24: ITT Population
Successful adherence to the prednisone taper from Week 12 through Week 24 was defined as participants who did not take rescue therapy from Week 12 through Week 24 and might include the use of any excess prednisone (beyond the per protocol CS tapering regimen) with a cumulative dose of <=100 mg (or equivalent), such as those employed to manage AE not related to GCA.
Total Cumulative Corticosteroid (Including Prednisone) Dose
Cumulative dose of CS used for GCA disease was defined as the dose taken up to the end of treatment, including expected prednisone in tapering regimen per protocol, CS used in rescue therapy and the use of commercial prednisone (an excess of <=100 mg of prednisone during the study treatment period employed to manage AE not related to GCA). The total cumulative CS dose was based on the total number of days with complete or partial intake, no imputation was done on missed tablets.
Time to First Giant Cell Arteritis Disease Flare
Time to first GCA flare was defined as the duration (in days) from randomization to first GCA flare after clinical remission (defined as resolution of signs and symptoms and normalization of CRP [<10 mg/L]) and up to 52 weeks. Disease flare was defined as either the recurrence of signs or symptoms attributable to active plus an increase in CS dose due to GCA or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA. Kaplan-Meier method was used for the analysis. Participants who never achieved remission were censored at randomization day; and those who achieved clinical remission and never flared were censored at the end of treatment assessment date up to Week 52.
Composite Glucocorticoid Toxicity Index (C-GTI): Cumulative Worsening Score (CWS) and Aggregate Improvement Score (AIS) at Week 24: ITT Population
GTI assessed glucocorticoid (GC) related morbidity and GC-sparing ability of other therapies; composed of 2 components: Composite GTI and Specific List. Composite GTI contained 9 domains and Specific List contained of 23 items (11 domains), used as complementary tool to C-GTI. Composite GTI score was the sum of 9 domain-specific scores at each visit and Cumulative GTI score was the sum of composite GTI scores across each visit. Two cumulative GTI scores: CWS and AIS at Week 24 are reported in this outcome measure (OM). CWS assessed cumulative GC toxicity regardless of whether toxicity had lasting effects or was transient. AIS assessed new therapy effectiveness in decreasing any Baseline GC toxicity over time. For CWS, composite score ranged from 0 to 439 and for AIS, composite score ranged from -346 to 439. For both CWS and AIS, the minimum score implies the least toxicity and the maximum score implies the most toxicity.
Composite Glucocorticoid Toxicity Index: Cumulative Worsening Score and Aggregate Improvement Score at Week 52
GTI assessed glucocorticoid (GC) related morbidity and GC-sparing ability of other therapies; composed of 2 components: Composite GTI and Specific List. Composite GTI contained 9 domains and Specific List contained of 23 items (11 domains), used as complementary tool to C-GTI. Composite GTI score was the sum of 9 domain-specific scores at each visit and Cumulative GTI score was the sum of composite GTI scores across each visit. Two cumulative GTI scores: CWS and AIS at Week 52 are reported in this OM. CWS assessed cumulative GC toxicity regardless of whether toxicity had lasting effects or was transient. AIS assessed new therapy effectiveness in decreasing any Baseline GC toxicity over time. For CWS, composite score ranged from 0 to 439 and for AIS, composite score ranged from -346 to 439. For both CWS and AIS, the minimum score implies the least toxicity and the maximum score implies the most toxicity.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. Serious AEs (SAEs) were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the investigational medicinal product (IMP) to the last dose of the SC IMP +60 days).
Pharmacokinetics (PK): Serum Trough Concentration (Ctrough) of Sarilumab
Ctrough was pre dose concentration of drug. Data for this outcome measure was not planned to be collected and analyzed for placebo arms (Placebo+52 Week Taper and Placebo+26 Week Taper) as pre-specified in the protocol.
Pharmacokinetics: Serum Drug Concentration of Sarilumab Post-dose at Week 24
Serum concentrations of functional sarilumab were analyzed using validated enzyme linked immunosorbent assay.
Percentage of Participants With Treatment-emergent Antidrug Antibodies (ADA) Response
ADA response categories: 1) Treatment-boosted ADA positive participant: Participant with a positive ADA assay response at Baseline and with at least a 4-fold increase in titer compared to Baseline during TEAE period. 2) Treatment-emergent ADA positive participant: Participant with non-positive assay (meaning negative or missing) response at Baseline but with a positive assay response during the TEAE period (defined as the time from the first dose of the IMP to the last dose of the SC IMP + 60 days). Titer values were categorized as low (titer <1,000); moderate (1,000<= titer <=10,000) and high (titer >10,000).
Pharmacodynamics: Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52
ESR is a laboratory test to provide non-specific measure of inflammation in the body. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimeters per hour.
Pharmacodynamics: Change From Baseline in C-reactive Protein (CRP) Level at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52
CRP is a protein made by the liver. CRP levels increase in blood when inflammation occurs in the body.
Pharmacodynamics: Change From Baseline in Interleukin-6 (IL-6) at Weeks 2, 12, 24, and 52
Interleukin-6 is a protein produced in the body. Levels of IL-6 often increase when there is inflammation (redness, warmth, swelling, and pain as a result of infection, irritation, or injury), either acute or chronic.
Pharmacodynamics: Change From Baseline in Soluble Interleukin-6 Receptor (sIL-6R) Level at Weeks 2, 12, 24, and 52
Interleukin-6 is a protein produced in the body. Levels of IL-6 often increase when there is inflammation (redness, warmth, swelling, and pain as a result of infection, irritation, or injury), either acute or chronic. sIL-6R is one of the receptors that bind IL-6.

Full Information

First Posted
July 17, 2018
Last Updated
March 15, 2022
Sponsor
Sanofi
Collaborators
Regeneron Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT03600805
Brief Title
Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
Official Title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Terminated
Why Stopped
Protracted recruitment timeline exacerbated by COVID-19 pandemic
Study Start Date
November 20, 2018 (Actual)
Primary Completion Date
November 24, 2020 (Actual)
Study Completion Date
November 24, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi
Collaborators
Regeneron Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary Objective: To evaluate the efficacy of sarilumab in participants with giant cell arteritis (GCA) as assessed by the proportion of participants with sustained remission for sarilumab compared to placebo, in combination with a corticosteroid (CS) tapering course. Secondary Objective: To demonstrate the efficacy of sarilumab in participants with GCA compared to placebo, in combination with CS taper with regards to: Clinical responses (such as responses based on disease remission rates, time to first disease flare) over time. Cumulative CS (including prednisone) exposure. To assess the safety (including immunogenicity) and tolerability of sarilumab in participants with GCA. To measure sarilumab serum concentrations in participants with GCA. To assess the effect of sarilumab on sparing glucocorticoid toxicity as measured by glucocorticoid toxicity index (GTI).
Detailed Description
Study duration per participant was approximately 82 weeks, including an up to 6-week screening period, 52-week treatment period, and 24-week follow-up period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Giant Cell Arteritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
83 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo+52 Week Taper
Arm Type
Experimental
Arm Description
Participants received sarilumab-matching placebo as subcutaneous (SC) injection every 2 weeks (q2w) up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone/prednisone-matching placebo tapering oral daily doses for 52 weeks.
Arm Title
Placebo+26 Week Taper
Arm Type
Experimental
Arm Description
Participants received sarilumab-matching placebo as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.
Arm Title
Sarilumab 150mg q2w+26 Week Taper
Arm Type
Placebo Comparator
Arm Description
Participants received sarilumab 150 milligrams (mg) as SC injection q2w up to 52 weeks along with prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.
Arm Title
Sarilumab 200mg q2w+26 Week Taper
Arm Type
Placebo Comparator
Arm Description
Participants received sarilumab 200 mg as SC injection q2w up to 52 weeks along with prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.
Intervention Type
Drug
Intervention Name(s)
Sarilumab SAR153191
Intervention Description
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Intervention Type
Drug
Intervention Name(s)
Sarilumab matching placebo
Intervention Description
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Intervention Type
Drug
Intervention Name(s)
Prednisone
Intervention Description
Pharmaceutical form: tablets or capsules Route of administration: oral administration
Intervention Type
Drug
Intervention Name(s)
Prednisone matching placebo
Intervention Description
Pharmaceutical form: capsules Route of administration: oral administration
Primary Outcome Measure Information:
Title
Percentage of Participants Who Achieved Sustained Disease Remission at Week 52
Description
Disease remission was defined as resolution of signs and symptoms of giant cell arteries (GCA), and normalization of C-reactive protein (CRP) (<10 mg/L). Sustained remission was defined as meeting all of the following parameters: achievement of disease remission not later than Week 12, absence of disease flare (defined as recurrence of signs and symptoms attributable to active GCA plus an increase in corticosteroid [CS] dose due to GCA or elevation of erythrocyte sedimentation rate [ESR] attributable to active GCA plus an increase in CS dose due to GCA) from Week 12 through Week 52, normalization of CRP (to <10 mg/L, with absence of successive elevations to >=10 mg/L) from Week 12 through Week 52, and successful adherence to prednisone taper from Week 12 through Week 52.
Time Frame
At Week 52
Title
Percentage of Participants Who Achieved Sustained Disease Remission at Week 24
Description
Disease remission was defined as resolution of signs and symptoms of GCA, and normalization of CRP <10 mg/L. Sustained remission was defined as meeting all of the following parameters: achievement of disease remission not later than Week 12, absence of disease flare (defined as recurrence of signs and symptoms attributable to active GCA plus an increase in CS dose due to GCA, or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA) from Week 12 through Week 24, normalization of CRP (to <10 mg/L, with an absence of successive elevations to >=10 mg/L) from Week 12 through Week 24, and successful adherence to the prednisone taper from Week 12 through Week 24.
Time Frame
At Week 24
Secondary Outcome Measure Information:
Title
Number of Participants With Achievement of Disease Remission up to Week 12: Week 52 Analysis Set
Description
Disease remission was defined as resolution of signs and symptoms of GCA, and normalization of CRP (< 10 mg/L). The status of normalization of CRP (<10 mg/L) was determined based on the last two non-missing post-baseline CRP values measured up to Week 12. If at least one of the value was <10 mg/L, then it was considered as normalization of CRP. Participants who took rescue corticosteroid (CS) due to active GCA prior to Week 12 or who permanently withdrew from the study treatment prior to Week 12 were considered as not achieved disease remission by Week 12.
Time Frame
Up to Week 12
Title
Number of Participants With Achievement of Disease Remission up to Week 12: Intent-to-treat (ITT) Population
Description
Disease remission was defined as resolution of signs and symptoms of GCA, and normalization of CRP (< 10 mg/L). The status of normalization of CRP (<10 mg/L) was determined based on the last two non-missing post-baseline CRP values measured up to Week 12. If at least one of the value was <10 mg/L, then it was considered as normalization of CRP. Participants who took rescue CS due to active GCA prior to Week 12 or who permanently withdrew from the study treatment prior to Week 12 were considered as not achieved disease remission by Week 12.
Time Frame
Up to Week 12
Title
Number of Participants With Absence of Disease Flare From Week 12 Through Week 52: Week 52 Analysis Set
Description
Disease flare was defined as either recurrence of signs and symptoms attributable to active GCA plus an increase in CS dose due to GCA, or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA. Number of participants with absence of disease flare from Week 12 through Week 52 were reported.
Time Frame
From Week 12 through Week 52
Title
Number of Participants With Absence of Disease Flare From Week 12 Through Week 24: ITT Population
Description
Disease flare was defined as either recurrence of signs and symptoms attributable to active GCA plus an increase in CS dose due to GCA, or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA. Number of participants with absence of disease flare from Week 12 through Week 24 were reported.
Time Frame
From Week 12 through Week 24
Title
Number of Participants With Normalization of C-Reactive Protein From Week 12 Through Week 52: Week 52 Analysis Set
Description
Normalization of CRP was defined as CRP levels <10 mg/L. If there were two or more consecutive visits with CRP >=10 mg/L, then it was categorized as no normalization of CRP.
Time Frame
From Week 12 through Week 52
Title
Number of Participants With Normalization of C-Reactive Protein (CRP) From Week 12 Through Week 24: ITT Population
Description
Normalization of CRP was defined as CRP levels <10 mg/L. If there were two or more consecutive visits with CRP >=10 mg/L, then it was categorized as no normalization of CRP.
Time Frame
From Week 12 through Week 24
Title
Number of Participants With Successful Adherence to the Prednisone Taper From Week 12 Through Week 52: Week 52 Analysis Set
Description
Successful adherence to the prednisone taper from Week 12 through Week 52 was defined as participants who did not take rescue therapy from Week 12 through Week 52 and might include the use of any excess prednisone (beyond the per protocol CS tapering regimen) with a cumulative dose of <=100 mg (or equivalent), such as those employed to manage adverse event (AE) not related to GCA.
Time Frame
From Week 12 through Week 52
Title
Number of Participants With Successful Adherence to the Prednisone Taper From Week 12 Through Week 24: ITT Population
Description
Successful adherence to the prednisone taper from Week 12 through Week 24 was defined as participants who did not take rescue therapy from Week 12 through Week 24 and might include the use of any excess prednisone (beyond the per protocol CS tapering regimen) with a cumulative dose of <=100 mg (or equivalent), such as those employed to manage AE not related to GCA.
Time Frame
From Week 12 through Week 24
Title
Total Cumulative Corticosteroid (Including Prednisone) Dose
Description
Cumulative dose of CS used for GCA disease was defined as the dose taken up to the end of treatment, including expected prednisone in tapering regimen per protocol, CS used in rescue therapy and the use of commercial prednisone (an excess of <=100 mg of prednisone during the study treatment period employed to manage AE not related to GCA). The total cumulative CS dose was based on the total number of days with complete or partial intake, no imputation was done on missed tablets.
Time Frame
Up to Week 52
Title
Time to First Giant Cell Arteritis Disease Flare
Description
Time to first GCA flare was defined as the duration (in days) from randomization to first GCA flare after clinical remission (defined as resolution of signs and symptoms and normalization of CRP [<10 mg/L]) and up to 52 weeks. Disease flare was defined as either the recurrence of signs or symptoms attributable to active plus an increase in CS dose due to GCA or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA. Kaplan-Meier method was used for the analysis. Participants who never achieved remission were censored at randomization day; and those who achieved clinical remission and never flared were censored at the end of treatment assessment date up to Week 52.
Time Frame
Up to Week 52
Title
Composite Glucocorticoid Toxicity Index (C-GTI): Cumulative Worsening Score (CWS) and Aggregate Improvement Score (AIS) at Week 24: ITT Population
Description
GTI assessed glucocorticoid (GC) related morbidity and GC-sparing ability of other therapies; composed of 2 components: Composite GTI and Specific List. Composite GTI contained 9 domains and Specific List contained of 23 items (11 domains), used as complementary tool to C-GTI. Composite GTI score was the sum of 9 domain-specific scores at each visit and Cumulative GTI score was the sum of composite GTI scores across each visit. Two cumulative GTI scores: CWS and AIS at Week 24 are reported in this outcome measure (OM). CWS assessed cumulative GC toxicity regardless of whether toxicity had lasting effects or was transient. AIS assessed new therapy effectiveness in decreasing any Baseline GC toxicity over time. For CWS, composite score ranged from 0 to 439 and for AIS, composite score ranged from -346 to 439. For both CWS and AIS, the minimum score implies the least toxicity and the maximum score implies the most toxicity.
Time Frame
At Week 24
Title
Composite Glucocorticoid Toxicity Index: Cumulative Worsening Score and Aggregate Improvement Score at Week 52
Description
GTI assessed glucocorticoid (GC) related morbidity and GC-sparing ability of other therapies; composed of 2 components: Composite GTI and Specific List. Composite GTI contained 9 domains and Specific List contained of 23 items (11 domains), used as complementary tool to C-GTI. Composite GTI score was the sum of 9 domain-specific scores at each visit and Cumulative GTI score was the sum of composite GTI scores across each visit. Two cumulative GTI scores: CWS and AIS at Week 52 are reported in this OM. CWS assessed cumulative GC toxicity regardless of whether toxicity had lasting effects or was transient. AIS assessed new therapy effectiveness in decreasing any Baseline GC toxicity over time. For CWS, composite score ranged from 0 to 439 and for AIS, composite score ranged from -346 to 439. For both CWS and AIS, the minimum score implies the least toxicity and the maximum score implies the most toxicity.
Time Frame
At Week 52
Title
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Description
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. Serious AEs (SAEs) were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the investigational medicinal product (IMP) to the last dose of the SC IMP +60 days).
Time Frame
From first dose (i.e., Day 1) up to 60 days after last dose (i.e., up to Week 60)
Title
Pharmacokinetics (PK): Serum Trough Concentration (Ctrough) of Sarilumab
Description
Ctrough was pre dose concentration of drug. Data for this outcome measure was not planned to be collected and analyzed for placebo arms (Placebo+52 Week Taper and Placebo+26 Week Taper) as pre-specified in the protocol.
Time Frame
Pre-dose on Week 0 (Baseline), Weeks 2, 4, 12, 16, 24 and 52
Title
Pharmacokinetics: Serum Drug Concentration of Sarilumab Post-dose at Week 24
Description
Serum concentrations of functional sarilumab were analyzed using validated enzyme linked immunosorbent assay.
Time Frame
post-dose at Week 24
Title
Percentage of Participants With Treatment-emergent Antidrug Antibodies (ADA) Response
Description
ADA response categories: 1) Treatment-boosted ADA positive participant: Participant with a positive ADA assay response at Baseline and with at least a 4-fold increase in titer compared to Baseline during TEAE period. 2) Treatment-emergent ADA positive participant: Participant with non-positive assay (meaning negative or missing) response at Baseline but with a positive assay response during the TEAE period (defined as the time from the first dose of the IMP to the last dose of the SC IMP + 60 days). Titer values were categorized as low (titer <1,000); moderate (1,000<= titer <=10,000) and high (titer >10,000).
Time Frame
From Day 1 (Baseline) up to last dose date of study drug + 60 days (i.e., up to Week 60)
Title
Pharmacodynamics: Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52
Description
ESR is a laboratory test to provide non-specific measure of inflammation in the body. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimeters per hour.
Time Frame
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52
Title
Pharmacodynamics: Change From Baseline in C-reactive Protein (CRP) Level at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52
Description
CRP is a protein made by the liver. CRP levels increase in blood when inflammation occurs in the body.
Time Frame
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52
Title
Pharmacodynamics: Change From Baseline in Interleukin-6 (IL-6) at Weeks 2, 12, 24, and 52
Description
Interleukin-6 is a protein produced in the body. Levels of IL-6 often increase when there is inflammation (redness, warmth, swelling, and pain as a result of infection, irritation, or injury), either acute or chronic.
Time Frame
Baseline, Weeks 2, 12, 24, and 52
Title
Pharmacodynamics: Change From Baseline in Soluble Interleukin-6 Receptor (sIL-6R) Level at Weeks 2, 12, 24, and 52
Description
Interleukin-6 is a protein produced in the body. Levels of IL-6 often increase when there is inflammation (redness, warmth, swelling, and pain as a result of infection, irritation, or injury), either acute or chronic. sIL-6R is one of the receptors that bind IL-6.
Time Frame
Baseline, Weeks 2, 12, 24, and 52

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria : Diagnosis of GCA according to European League Against Rheumatism/American College of Rheumatology classification criteria. New onset active disease or refractory active disease. At least one of the symptoms of GCA within 6 weeks of baseline. Either erythrocyte sedimentation rate greater than or equal to (>=) 30 millimeter per hour or C-reactive protein >=10 mg per liter within 6 weeks of baseline. Received or were able to receive prednisone 20-60 mg/day for the treatment of active GCA. Exclusion criteria: Organ transplantation recipient (except corneas, unless it is within 3 months prior to baseline visit). Major ischemic event, unrelated to GCA, within 12 weeks of screening. Any prior use of the following therapies, for the treatment of GCA: Janus kinase inhibitor (e.g., tofacitinib) within 4 weeks of baseline. Cell-depletion agents (e.g., anti CD20) without evidence of recovery of B cells to baseline level. Abatacept within 8 weeks of baseline. Anakinra within 1 week of baseline. Tumor necrosis factor inhibitors within 2-8 weeks (etanercept within 2 weeks; infliximab, certolizumab, golimumab, or adalimumab within 8 weeks), or less than at least 5 half-lives had elapsed prior to baseline, whichever was longer. Therapeutic failure, including inadequate response or intolerance, or contraindication, to biological Interleukin 6 (IL-6) IL-6/(R) antagonist (prior experience with IL-6/(R) antagonist that was terminated for reasons unrelated to therapeutic failure at least 3 months before baseline was not exclusionary). Use of any alkylating agents including cyclophosphamide within 6 months of baseline. Use of immunosuppressant, such as hydroxychloroquine, cyclosporine, azathioprine, mycophenolate mofetil or leflunomide within 4 weeks of baseline. (Use of methotrexate (MTX) not exceeding 25 mg per week and had been stable for at least 3 months prior to baseline was not exclusionary). Concurrent use of systemic CS for conditions other than GCA. Use of intervascular CS at a dose equivalent to 100 mg of methylprednisolone or higher within 8 weeks of baseline for GCA therapy. Pregnant or breastfeeding woman. Participants with active or untreated latent tuberculosis. Participants with history of invasive opportunistic infections. Participants with fever associated with infection or chronic, persistent or recurring infections requiring active treatment. Participants with uncontrolled diabetes mellitus. Participants with non-healed or healing skin ulcers. Participants who received any live, attenuated vaccine within 3 months of baseline. Participants who are positive for hepatitis B, hepatitis C and/or HIV. Participants with a history of active or recurrent herpes zoster. Participants with a history of or prior articular or prosthetic joint infection. Prior or current history of malignancy. Participants who have had surgery within 4 weeks of screening or planned surgery during study. Participants with a history of inflammatory bowel disease or severe diverticulitis or previous gastrointestinal perforation.. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Investigational Site Number 8400002
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33486
Country
United States
Facility Name
Investigational Site Number 8400017
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32608
Country
United States
Facility Name
Investigational Site Number 8400014
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Facility Name
Investigational Site Number 8400018
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
Investigational Site Number 8400019
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Investigational Site Number 8400011
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Facility Name
Investigational Site Number 0320001
City
Buenos Aires
ZIP/Postal Code
C1015ABO
Country
Argentina
Facility Name
Investigational Site Number 0320002
City
Caba
ZIP/Postal Code
C1181ACH
Country
Argentina
Facility Name
Investigational Site Number 0360003
City
Camberwell
ZIP/Postal Code
3124
Country
Australia
Facility Name
Investigational Site Number 0360006
City
Clayton
ZIP/Postal Code
3168
Country
Australia
Facility Name
Investigational Site Number 0360001
City
Kogarah
ZIP/Postal Code
2217
Country
Australia
Facility Name
Investigational Site Number 0560001
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Investigational Site Number 1240007
City
Hamilton
ZIP/Postal Code
L8N 4A6
Country
Canada
Facility Name
Investigational Site Number 1240010
City
Montreal
ZIP/Postal Code
H4A 3T2
Country
Canada
Facility Name
Investigational Site Number 1240001
City
Rimouski
ZIP/Postal Code
G5L 5T1
Country
Canada
Facility Name
Investigational Site Number 1240005
City
Sherbrooke
ZIP/Postal Code
J1G 2E8
Country
Canada
Facility Name
Investigational Site Number 1240003
City
Trois-Rivières
ZIP/Postal Code
G8Z 1Y2
Country
Canada
Facility Name
Investigational Site Number 1910001
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Facility Name
Investigational Site Number 2080002
City
Aarhus C
ZIP/Postal Code
8000
Country
Denmark
Facility Name
Investigational Site Number 2080003
City
Svendborg
ZIP/Postal Code
5700
Country
Denmark
Facility Name
Investigational Site Number 2330001
City
Tallinn
ZIP/Postal Code
13419
Country
Estonia
Facility Name
Investigational Site Number 2500005
City
Brest Cedex
ZIP/Postal Code
29609
Country
France
Facility Name
Investigational Site Number 2500002
City
Montivilliers
ZIP/Postal Code
76290
Country
France
Facility Name
Investigational Site Number 2500003
City
Montpellier
ZIP/Postal Code
34295
Country
France
Facility Name
Investigational Site Number 2500007
City
Mulhouse
ZIP/Postal Code
68100
Country
France
Facility Name
Investigational Site Number 2500001
City
Paris
ZIP/Postal Code
75014
Country
France
Facility Name
Investigational Site Number 2500006
City
Pessac
ZIP/Postal Code
33604
Country
France
Facility Name
Investigational Site Number 2760001
City
Berlin
ZIP/Postal Code
13125
Country
Germany
Facility Name
Investigational Site Number 2760002
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Investigational Site Number 2760003
City
Kirchheim Unter Teck
ZIP/Postal Code
73230
Country
Germany
Facility Name
Investigational Site Number 2760004
City
München
ZIP/Postal Code
80336
Country
Germany
Facility Name
Investigational Site Number 2760007
City
Tübingen
ZIP/Postal Code
72076
Country
Germany
Facility Name
Investigational Site Number 3480001
City
Debrecen
ZIP/Postal Code
4032
Country
Hungary
Facility Name
Investigational Site Number 3760006
City
Ashkelon
ZIP/Postal Code
78278
Country
Israel
Facility Name
Investigational Site Number 3760004
City
Haifa
ZIP/Postal Code
34362
Country
Israel
Facility Name
Investigational Site Number 3800001
City
Milano
ZIP/Postal Code
20132
Country
Italy
Facility Name
Investigational Site Number 3800005
City
Rozzano
ZIP/Postal Code
20089
Country
Italy
Facility Name
Investigational Site Number 5280007
City
Den Haag
ZIP/Postal Code
2545 CH
Country
Netherlands
Facility Name
Investigational Site Number 5280005
City
Leeuwarden
ZIP/Postal Code
8934 AD
Country
Netherlands
Facility Name
Investigational Site Number 5280009
City
Sittard-Geleen
ZIP/Postal Code
6162 BG
Country
Netherlands
Facility Name
Investigational Site Number 5280001
City
Venlo
ZIP/Postal Code
5912 BL
Country
Netherlands
Facility Name
Investigational Site Number 6200001
City
Almada
ZIP/Postal Code
2801-951
Country
Portugal
Facility Name
Investigational Site Number 6200005
City
Aveiro
ZIP/Postal Code
3810-501
Country
Portugal
Facility Name
Investigational Site Number 6200004
City
Ponte De Lima
ZIP/Postal Code
4990-041
Country
Portugal
Facility Name
Investigational Site Number 6430005
City
Kemerovo
ZIP/Postal Code
650000
Country
Russian Federation
Facility Name
Investigational Site Number 6430002
City
Moscow
ZIP/Postal Code
115404
Country
Russian Federation
Facility Name
Investigational Site Number 6430003
City
Moscow
ZIP/Postal Code
123182
Country
Russian Federation
Facility Name
Investigational Site Number 7050001
City
Ljubljana
ZIP/Postal Code
1000
Country
Slovenia
Facility Name
Investigational Site Number 7240010
City
Bilbao
ZIP/Postal Code
48013
Country
Spain
Facility Name
Investigational Site Number 7240011
City
La Coruña
ZIP/Postal Code
15006
Country
Spain
Facility Name
Investigational Site Number 7240014
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
Investigational Site Number 7240016
City
Sabadell
ZIP/Postal Code
08208
Country
Spain
Facility Name
Investigational Site Number 7240015
City
Santa Cruz De Tenerife
ZIP/Postal Code
38320
Country
Spain
Facility Name
Investigational Site Number 7520001
City
Uppsala
ZIP/Postal Code
751 85
Country
Sweden
Facility Name
Investigational Site Number 7520003
City
Örebro
ZIP/Postal Code
701 85
Country
Sweden
Facility Name
Investigational Site Number 7560002
City
St. Gallen
ZIP/Postal Code
9007
Country
Switzerland
Facility Name
Investigational Site Number 8260006
City
Aberdeen
ZIP/Postal Code
AB25 2ZN
Country
United Kingdom
Facility Name
Investigational Site Number 8260004
City
Gateshead
ZIP/Postal Code
NE9 6SX
Country
United Kingdom
Facility Name
Investigational Site Number 8260003
City
Leeds
ZIP/Postal Code
LS7 4SA
Country
United Kingdom
Facility Name
Investigational Site Number 8260005
City
Manchester
ZIP/Postal Code
M13 9WL
Country
United Kingdom
Facility Name
Investigational Site Number 8260011
City
Portsmouth
ZIP/Postal Code
PO6 3LY
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Learn more about this trial

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

We'll reach out to this number within 24 hrs